ECC 5004
Alternative Names: AZD-5004; ECC-5004Latest Information Update: 04 Sep 2024
At a glance
- Originator AstraZeneca; Eccogene
- Developer Eccogene
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Sep 2024 AstraZeneca plans phase II SOLSTICE trial in Type 2 diabetes mellitus in US, Canada, Germany, Hungary, Japan, Poland, Slovakia, Spain and United Kingdom in October 2024 (PO) (NCT06579105)
- 04 Sep 2024 AstraZeneca plans phase II VISTA trial in Obesity in US, Australia, Canada, Germany, Taiwan and United Kingdom in October 2024 (PO)(NCT06579092)
- 21 Aug 2024 AstraZeneca plans a phase I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT06555822)